Natalie C DuPre1,2, Richard Flavin3, Karen S Sfanos4, Robert H Unger1, Samantha To5, Elizaveta Gazeeva6, Michelangelo Fiorentino1,7, Angelo M De Marzo4, Jennifer R Rider8, Lorelei A Mucci1. 1. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 2. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. Department of Histopathology, St. James's Hospital and Trinity College, Dublin, Ireland. 4. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Massachusetts. 5. Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts. 6. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 7. Pathology Unit, Addarii Instituto, S. Orsola-Malpighi Hospital, Bologna, Italy. 8. Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.
Abstract
BACKGROUND: Corpora amylacea are amyloid bodies commonly found adjacent to damaged prostate epithelium. Little is known about their formation or function. The current study sought to characterize corpora amylacea in prostate tissue and to describe their relationship with clinical, histological, molecular, and lifestyle factors, especially with chronic inflammation which is associated with aggressive disease. METHODS: We studied a cohort of 355 men with prostate cancer and tissue specimens from the Health Professionals Follow-Up Study. Pathologists examined H&E slides and undertook a standardized review for histologic data and inflammation. Trained observers counted corpora amylacea within the benign and predominately tumor areas. Immunohistochemistry biomarkers were available from tissue microarrays. We used multivariable logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) to assess associations of chronic inflammation, clinical, histological, molecular, and lifestyle factors with the presence of corpora amylacea. RESULTS: Corpora amylacea were present in benign tissue area for 298 men (84%). Specimens with moderate-to-severe chronic inflammation were more likely to have corpora amylacea in benign regions (OR = 5.4 95%CI 1.9, 15.6). Moreover, corpora amylacea were more common in men with higher body mass index (OR = 1.13 95%CI 1.01, 1.26). In contrast, Gleason grade (OR = 0.4 95%CI 0.2, 0.8), proliferation index (OR = 0.6 95%CI 0.3, 1.2) and the presence of the TMPRSS2:ERG fusion (OR = 0.4 95%CI 0.2, 0.8) were inversely associated with corpora amylacea presence. TURP specimens were less likely to have corpora amylacea than prostatectomy specimens (OR = 0.12 95%CI 0.03, 0.47). Age, PSA, stage, biomarkers of angiogenesis and PTEN, and vasectomy were not significantly associated with corpora amylacea. CONCLUSION: Corpora amylacea were common among men with prostate cancer and were associated with pro-inflammatory factors, some markers of less aggressive disease, and lack of the TMPRSS2:ERG fusion.
BACKGROUND: Corpora amylacea are amyloid bodies commonly found adjacent to damaged prostate epithelium. Little is known about their formation or function. The current study sought to characterize corpora amylacea in prostate tissue and to describe their relationship with clinical, histological, molecular, and lifestyle factors, especially with chronic inflammation which is associated with aggressive disease. METHODS: We studied a cohort of 355 men with prostate cancer and tissue specimens from the Health Professionals Follow-Up Study. Pathologists examined H&E slides and undertook a standardized review for histologic data and inflammation. Trained observers counted corpora amylacea within the benign and predominately tumor areas. Immunohistochemistry biomarkers were available from tissue microarrays. We used multivariable logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) to assess associations of chronic inflammation, clinical, histological, molecular, and lifestyle factors with the presence of corpora amylacea. RESULTS: Corpora amylacea were present in benign tissue area for 298 men (84%). Specimens with moderate-to-severe chronic inflammation were more likely to have corpora amylacea in benign regions (OR = 5.4 95%CI 1.9, 15.6). Moreover, corpora amylacea were more common in men with higher body mass index (OR = 1.13 95%CI 1.01, 1.26). In contrast, Gleason grade (OR = 0.4 95%CI 0.2, 0.8), proliferation index (OR = 0.6 95%CI 0.3, 1.2) and the presence of the TMPRSS2:ERG fusion (OR = 0.4 95%CI 0.2, 0.8) were inversely associated with corpora amylacea presence. TURP specimens were less likely to have corpora amylacea than prostatectomy specimens (OR = 0.12 95%CI 0.03, 0.47). Age, PSA, stage, biomarkers of angiogenesis and PTEN, and vasectomy were not significantly associated with corpora amylacea. CONCLUSION: Corpora amylacea were common among men with prostate cancer and were associated with pro-inflammatory factors, some markers of less aggressive disease, and lack of the TMPRSS2:ERG fusion.
Authors: D Hoyaux; C Decaestecker; C W Heizmann; T Vogl; B W Schäfer; I Salmon; R Kiss; R Pochet Journal: Brain Res Date: 2000-06-09 Impact factor: 3.252
Authors: Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-26 Impact factor: 4.254
Authors: Jennifer R Rider; Michelangelo Fiorentino; Rachel Kelly; Travis Gerke; Kristina Jordahl; Jennifer A Sinnott; Edward L Giovannucci; Massimo Loda; Lorelei A Mucci; Stephen Finn Journal: Carcinogenesis Date: 2015-04-11 Impact factor: 4.944
Authors: Whitney K Hendrickson; Richard Flavin; Julie L Kasperzyk; Michelangelo Fiorentino; Fang Fang; Rosina Lis; Christopher Fiore; Kathryn L Penney; Jing Ma; Philip W Kantoff; Meir J Stampfer; Massimo Loda; Lorelei A Mucci; Edward Giovannucci Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Rebecca E Graff; Carlos L Morais; Jessica L Hicks; Kathryn M Wilson; Jennifer R Rider; Howard D Sesso; Michelangelo Fiorentino; Richard Flavin; Stephen Finn; Edward L Giovannucci; Massimo Loda; Meir J Stampfer; Angelo M De Marzo; Lorelei A Mucci; Tamara L Lotan Journal: J Natl Cancer Inst Date: 2015-11-27 Impact factor: 13.506
Authors: Stuart P Weisberg; Daniel McCann; Manisha Desai; Michael Rosenbaum; Rudolph L Leibel; Anthony W Ferrante Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: Rebecca E Graff; Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Kathryn L Penney; Kathryn M Wilson; Sarah C Markt; Claire H Pernar; Amparo G Gonzalez-Feliciano; Mingyang Song; Rosina T Lis; Daniel R Schmidt; Matthew G Vander Heiden; Michelangelo Fiorentino; Edward L Giovannucci; Massimo Loda; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-22 Impact factor: 4.254
Authors: Francesco Cambuli; Veronica Foletto; Alessandro Alaimo; Dario De Felice; Francesco Gandolfi; Maria Dilia Palumbieri; Michela Zaffagni; Sacha Genovesi; Marco Lorenzoni; Martina Celotti; Emiliana Bertossio; Giosuè Mazzero; Arianna Bertossi; Alessandra Bisio; Francesco Berardinelli; Antonio Antoccia; Marco Gaspari; Mattia Barbareschi; Michelangelo Fiorentino; Michael M Shen; Massimo Loda; Alessandro Romanel; Andrea Lunardi Journal: EMBO Rep Date: 2022-03-07 Impact factor: 9.071
Authors: Johann S de Bono; Christina Guo; Bora Gurel; Angelo M De Marzo; Karen S Sfanos; Ram S Mani; Jesús Gil; Charles G Drake; Andrea Alimonti Journal: Nat Rev Cancer Date: 2020-06-16 Impact factor: 60.716